Hotel Dieu Of France University Hospital Hdf

Beirut, Lebanon

Hotel Dieu Of France University Hospital Hdf

Beirut, Lebanon
SEARCH FILTERS
Time filter
Source Type

Tabchi S.,Hotel Dieu Of France University Hospital Hdf | Kourie H.R.,Hotel Dieu Of France University Hospital Hdf | Farhat F.,Hotel Dieu Of France University Hospital Hdf | Kattan J.,Hotel Dieu Of France University Hospital Hdf
Journal Medical Libanais | Year: 2016

Introduction : Advanced pancreatic cancer (APC), one of the most aggressive tumors, was considered to be resistant to chemotherapy for decades. FOLFIRINOX (5-FU, leucovorin, irinotecan and oxaliplatin) regimen showed an improvement of quality of life and overall survival in APC patients with good performance status (ECOG < 2). Material and methods : Seven patients diagnosed with APC, during a six-month period, received FOLFIRINOX as first line treatment. Tumor measurement was assessed every two months and CA 19-9, the specific tumor marker of pancreatic cancer, was assessed every two weeks at every cycle. Results : Three patients out of seven receiving FOLFIRINOX experienced an early and transitory increase of CA 19-9 after the first two cycles resulting in a considerable response with a median survival of 15 months and suggesting a model of tumor release syndrome. Conclusion: This phenomenon of early and transitory increase of CA 19-9 in APC could reflect the high efficacy of FOLFIRINOX and could predict better outcome in these patients.

Loading Hotel Dieu Of France University Hospital Hdf collaborators
Loading Hotel Dieu Of France University Hospital Hdf collaborators